# Food-Grade Microgels for Age-Related Macular Degeneration: Design, Fabrication, and Targeted Delivery

**Authors:** Sun Ju Kim, Dong Yoon Kim, Daehyeok Jeong, Changmin Lee, Hyun-Dong Cho, Minsoo P. Kim

PMC · DOI: 10.3390/gels12030252 · 2026-03-17

## TL;DR

This paper explores how food-grade microgels can improve the delivery of nutrients to treat age-related macular degeneration, a leading cause of vision loss.

## Contribution

The paper introduces a novel integration of the gut-eye axis with microgel-based delivery systems for AMD treatment.

## Key findings

- Food-grade microgels can enhance nutrient stability and delivery for AMD treatment.
- Programmable release mechanisms in the gastrointestinal tract improve retinal delivery of bioactives.
- Co-encapsulation strategies allow synergistic modulation of oxidative and inflammatory pathways in AMD.

## Abstract

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss worldwide and is driven by complex pathophysiological processes, including oxidative stress, chronic inflammation, complement dysregulation, and vascular endothelial growth factor (VEGF)-mediated neovascularization. Nutritional interventions—particularly supplementation with carotenoids, omega-3 fatty acids, polyphenols, and essential micronutrients—have demonstrated clinical benefits in slowing disease progression, as evidenced by landmark trials such as AREDS and AREDS2. However, many AMD-relevant bioactives exhibit poor aqueous solubility, low chemical stability, and limited gastrointestinal bioavailability, which significantly constrain their therapeutic efficacy. Food-grade microgels have emerged as versatile colloidal delivery platforms capable of addressing these limitations through rational structural and physicochemical design. This review provides a systematic roadmap for developing food-grade microgels, organized into: (1) the molecular design of protein- and polysaccharide-based networks; (2) advanced fabrication strategies such as microfluidics and atomization; (3) spatiotemporal release programming within the gastrointestinal tract; and (4) multi-nutrient synergy for retinal protection. This approach highlights how controlled crosslinking, interfacial assembly, and tunable network architectures enhance nutrient stabilization. Particular emphasis is placed on spatiotemporal release programming within the gastrointestinal tract, including diffusion-limited gastric retention, pH- and bile-responsive swelling in the small intestine, and microbiota-triggered degradation in the colon. These mechanisms collectively enable region-specific release, improved micellar incorporation, enhanced systemic absorption, and more consistent retinal delivery. Furthermore, we discuss co-encapsulation strategies that accommodate both hydrophilic and lipophilic bioactives, thereby minimizing antagonistic interactions and enabling synergistic nutritional modulation of oxidative and inflammatory pathways implicated in AMD. A central novelty of this review is the integration of the gut–eye axis, framing microgel-based oral delivery as a systemic pathway to modulate retinal health via the intestinal environment. By bridging retinal disease biology with food colloid science, this review proposes food-grade microgels as a translational platform for next-generation nutraceutical interventions. The integration of programmable release behavior with clinically validated nutrient regimens offers a promising pathway toward more effective and mechanistically informed dietary management of AMD.

## Linked entities

- **Diseases:** age-related macular degeneration (MONDO:0005150), AMD (MONDO:0005150)

## Full-text entities

- **Genes:** TEK (TEK receptor tyrosine kinase) [NCBI Gene 7010] {aka CD202B, GLC3E, TIE-2, TIE2, VMCM, VMCM1}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, ANGPT2 (angiopoietin 2) [NCBI Gene 285] {aka AGPT2, ANG2, LMPHM10}, STARD3 (StAR related lipid transfer domain containing 3) [NCBI Gene 10948] {aka CAB1, MLN64, es64}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, PGF (placental growth factor) [NCBI Gene 5228] {aka D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760}, mucin [NCBI Gene 100508689], FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, SCARB1 (scavenger receptor class B member 1) [NCBI Gene 949] {aka CD36L1, CLA-1, CLA1, HDLCQ6, HDLQTL6, SR-BI}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, PDGFB (platelet derived growth factor subunit B) [NCBI Gene 5155] {aka IBGC5, PDGF-2, PDGF2, SIS, SSV, c-sis}, VEGFB (vascular endothelial growth factor B) [NCBI Gene 7423] {aka VEGFL, VRF}
- **Diseases:** drusen (MESH:D015593), mitochondrial (MESH:D028361), diabetes (MESH:D003920), complement (MESH:D007153), inflammatory damage (MESH:D018746), PCV (MESH:D000092342), cardiovascular dysfunction (MESH:D002318), gut dysbiosis (MESH:D064806), CNV (MESH:D020256), RPE detachment (MESH:D012163), RPE degeneration (MESH:D012162), long-term retinal health (MESH:D000088562), disease (MESH:D004194), injury to (MESH:D014947), hemorrhage (MESH:D006470), atrophic (MESH:D020966), retinal cell loss (MESH:D012173), metabolic dysregulation (MESH:D021081), inflammation (MESH:D007249), neovascular (MESH:D016510), photoreceptor degeneration (MESH:D009410), complement dysregulation (OMIM:614878), hypertension (MESH:D006973), gastric irritation (MESH:D013272), vision loss (MESH:D014786), chronic (MESH:D002908), geographic atrophy (MESH:D057092), hypoxia (MESH:D000860), photoreceptor loss (MESH:D016388), blindness (MESH:D001766), exudative disease (MESH:D011504), AMD (MESH:D008268), retinal damage (MESH:D012164)
- **Chemicals:** Fat (MESH:D005223), Lipids (MESH:D008055), starch (MESH:D013213), verteporfin (MESH:D000077362), Polysaccharide (MESH:D011134), brolucizumab (MESH:C000622091), zeaxanthin (MESH:D065146), Carotenoids (MESH:D002338), CaCl2 (MESH:D002122), pectin (MESH:D010368), zinc (MESH:D015032), DHA (MESH:C027493), lipofuscin (MESH:D008062), gellan (MESH:C048288), beta-carotene (MESH:D019207), Pegcetacoplan (MESH:C000716074), Fe (MESH:D007501), alcohol (MESH:D000438), Chitosan (MESH:D048271), resveratrol (MESH:D000077185), sulfhydryl (MESH:D013438), disulfide (MESH:D004220), anthocyanins (MESH:D000872), O (MESH:D010100), guluronic acid (MESH:C007896), Antioxidant vitamins (-), luminal (MESH:D010634), polymer (MESH:D011108), hydrogen (MESH:D006859), calcium (MESH:D002118), curcumin (MESH:D003474), biopolymer (MESH:D001704), monoacylglycerols (MESH:D050178), faricimab (MESH:C000723200), water (MESH:D014867), essential fatty acids (MESH:D005228), free fatty acids (MESH:D005230), XG (MESH:C002563), Polyphenols (MESH:D059808), Ranibizumab (MESH:D000069579), metal (MESH:D008670), Ascorbic acid (MESH:D001205), cellulose (MESH:D002482), carrageenan (MESH:D002351), Alginate (MESH:D000464), bile salt (MESH:D001647), Microgel (MESH:D000080386), lutein (MESH:D014975), omega-3 fatty acids (MESH:D015525), meso-zeaxanthin (MESH:C584722), oil (MESH:D009821), carbonate (MESH:D002254), Bevacizumab (MESH:D000068258), reactive oxygen species (MESH:D017382), astaxanthin (MESH:C005948), gum arabic (MESH:D006170), W (MESH:D014414), vitamin E (MESH:D014810), xanthophylls (MESH:D024341), retinal (MESH:D012172)
- **Species:** Bombyx mori (domestic silkworm, species) [taxon 7091], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rodentia (rodent, order) [taxon 9989]
- **Cell lines:** RPE — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_IQ82)

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025106/full.md

---
Source: https://tomesphere.com/paper/PMC13025106